Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys in Chronic Hepatitis D
NCT02732639Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2005
- Primary completion
- Dec 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peginterferon alfa-2a in chronic hepatitis D, sponsored by Roche. Primary endpoints: Percentage of Participants With Normal Alanine Aminotransferase at 72 weeks and Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid at 72 weeks. Started Oct 2005; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT02732639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732639.